SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of violations of federal securities laws, particularly concerning misleading statements about its product SLK compared to BIMZELX [3][5]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against MoonLake [3]. - The complaint alleges that MoonLake and its executives made false and misleading statements regarding the efficacy and clinical benefits of SLK compared to traditional monoclonal antibodies [5]. - Investors who suffered losses between March 10, 2024, and September 29, 2025, are encouraged to contact the firm to discuss their legal options [1][8]. Group 2: Stock Performance and Impact - Following the announcement of disappointing results from the Phase 3 VELA program on September 28, 2025, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [6]. - The results indicated that SLK did not demonstrate competitive efficacy relative to BIMZELX, which contributed to the significant drop in stock price [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].